At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 27 enrolled
Drug / intervention
Teriparatide 40-mcg subcutaneous injection +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
In Brief
A Phase 4 clinical trial evaluating Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, and 1 other intervention for Postmenopausal Osteoporosis. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Osteoporosis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 2012
Enrollment StartJan 2013
Primary CompletionApr 2014
Study CompletionAug 2014
TodayJul 2026
First PostedDec 17, 2012
Enrollment StartJan 1, 2013
Primary CompletionApr 1, 2014
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.5 years ago
Interventions
Teriparatide 40-mcg subcutaneous injectiondrug
Denosumab Injectiondrug
One-time Denosumab injection
Alendronate Oral Tabletdrug
weekly alendronate for 8 weeks